Postcovid-19 war era, hematologic disorders significantly increased by Covid-19 variants, mysteriously

Abstract

COVID-19 mutant(s)’ attacks are not over yet. Most people who developed COVID-19 infection fully recovered, but current confirmation suggests approximately 10%-20% of people experience a variety of mid- and long-term effects after they recovered from their initial illness. Besides, isolated blood products transfusion is a lifesaving procedure but hematologic disorders after transfusion accelerate morbidity and mortality rates, however. Platelet (hypo-)hyperactivity and dysfunction in different COVID-19 patients were already known facts but whether COVID-19 different variants could activate and/or accelerate death triangle machinery in diabetic and cancer patients, which can initiate synergistic interaction is not entirely elucidated yet. Deficiencies over standard protocols and golden standards in blood transfusion and biological products are of considerable concern now (March 2023). Subsequently, the management of almost all-natural products produced recently and biosimilar and their associated quality controls endure significant ignoring problems. What we learned from the last 3 years pandemic was that different blood banks isolated products still are potential hazardous factors to cause accelerated death and/or recovery; if they (in-)appropriately applied, curiously. In this mini-review is tried to unravel different potential changes, relationships, and associations between lifesaving (blood transfusion, isolated blood products) versus not-lifesaving approaches/procedures after 2023. Besides it tried to highlight specific context and rationale, especially concerning main factors that are playing a crucial role in the Pandemic separately, and/or together in an additive and/or synergistic way, to increase chronic postcovid-19 side effects/ collateral damages to longcovid patients.